Carregant...
Preclinical study of CC223 as a potential anti-ovarian cancer agent
Aberrant activation of mTOR contributes to ovarian cancer progression. CC223 is a novel and potent mTOR kinase inhibitor. The current study tested its activity against human ovarian cancer cells. We showed that CC223, at nM concentrations, inhibited survival and proliferation of established/primary...
Guardat en:
| Publicat a: | Oncotarget |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Impact Journals LLC
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5601667/ https://ncbi.nlm.nih.gov/pubmed/28938571 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17753 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|